MedTrace Logo

Bipolar Sealer for Reduction of Blood Loss in Anterior Total Hip Arthroplasties

NCT05356637 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-10-31

No results posted yet for this study

Summary

The overall objectives and purpose of this study is to show that the Smith and Nephew Werewolf Fastseal 6.0 Bipolar Sealer is an effective tool to aide the surgical team in providing significant hemostasis during anterior total hip arthroplasty which would subsequently improve patient outcomes.

Conditions

  • Osteoarthritis, Hip
  • Blood Loss

Interventions

DEVICE

Werewolf Fastseal 6.0

bi-polar hemostatic wand

Sponsors & Collaborators

  • Smith & Nephew, Inc.

    collaborator INDUSTRY

  • North Texas Medical Research Institute, PLLC

    lead OTHER

Principal Investigators

  • Mohammad U Burney, MD · NTMRI, OSD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-29
Primary Completion
2024-01-31
Completion
2024-02-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05356637 on ClinicalTrials.gov